Search

Your search keyword '"Boyer, Michelle"' showing total 186 results
Start Over Author "Boyer, Michelle"
186 results on '"Boyer, Michelle"'

1. S201: FINAL 7‐YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX‐RITUXIMAB (VENR)‐TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)

Author

Kater, Arnon, Harrup, Rosemary, Kipps, Thomas J, Eichhorst, Barbara, Owen, Carolyn J, Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Thadani‐Mulero, Maria, Lefebure, Marcus, Jiang, Yanwen, Millen, Rosemary, Boyer, Michelle, and Seymour, John F

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Lymphatic Research, Cancer, Lymphoma, Rare Diseases, Hematology
Published
2023

2. Interim Assessment Practices for Students with Disabilities. NCEO Brief Number 22

Author

National Center on Educational Outcomes, National Center for the Improvement of Educational Assessment, Inc. (NCIEA), Boyer, Michelle, and Landl, Erika

Abstract

This Brief contains a scan of the interim assessment landscape, and is focused on the availability of documentation supporting the appropriateness of these assessments for students with disabilities. The purpose of this Brief is to advise the development of guidance that facilitates improved practices related to the use of interim assessments for students with disabilities.

Published
2021

3. Making Sense of Spring 2021 Assessment Results

Author

National Center for the Improvement of Educational Assessment, Inc. (NCIEA), Dadey, Nathan, Keng, Leslie, Boyer, Michelle, and Marion, Scott

Abstract

State summative educational assessment is about to begin in earnest. Rightfully, many are raising questions about the quality, meaning, and appropriate use of the assessment results. This document was written to support state educational agencies (SEAs) and their assessment providers in devising effective and efficient analysis plans. This document outlines two key strands of analyses for the spring 2021 assessment results: operational and investigative. The operational stand deals with analyses meant to support the "technical quality" of assessment scores and the intended interpretation(s) of the assessment results. The investigative strand deals with analyses meant to aid in understanding the "effects" of pandemic-related disruptions on student performance. Taken together, these two related strands make up a framework that is meant to help SEAs and their assessment providers make sense of student performance on spring 2021 summative assessments. This framework, and the recommendations in this report, are informed by emerging work in educational measurement as well as prior publications in this field. First, a logic model for structuring analyses based on spring 2021 data is presented, which is followed by a summary of the operational and investigative strands of analyses. For each strand a non-exhaustive list of questions and related analyses is presented. The report concludes with considerations for implementing these analyses. This framework is meant to support planning "now," rather than waiting for scores to be returned. Assessment administration this year will be quite different from normal in most cases, requiring additional analyses conducted on accelerated timelines.

Published
2021

4. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Author

Al-Sawaf, Othman, Robrecht, Sandra, Zhang, Can, Olivieri, Stefano, Chang, Yi Meng, Fink, Anna Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Kreuzer, Karl-Anton, Sivchev, Liliya, Niemann, Carsten Utoft, Schwarer, Anthony, Loscertales, Javier, Weinkove, Robert, Strumberg, Dirk, Kilfoyle, Allanah, Manzoor, Beenish S., Jawaid, Dureshahwar, Emechebe, Nnadozie, Devine, Jacob, Boyer, Michelle, Runkel, Eva D., Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael, and Fischer, Kirsten

Published
2024
Full Text
View/download PDF

5. Statewide Summative Assessment in Spring 2021: A Workbook to Support Planning and Decision-Making. Version 1.0

Author

National Center for the Improvement of Educational Assessment, Inc. (NCIEA), Boyer, Michelle, Dadey, Nathan, and Keng, Leslie

Abstract

This school year, every state education agency (SEA) is faced with unprecedented, COVID-19-related challenges for the implementation of 2021 statewide summative assessments. Two overarching challenges are in how tests will be administered, and how scores will be interpreted and used, with many intervening and related challenges. Test administrations may necessarily look different in 2021. They may occur at atypical intervals, over longer periods of time, and they may be administered in whole, or in part to students who are logging in and testing remotely from their homes. Second the very nature of learning and assessment in remote or hybrid environments during the year preceding Spring 2021 assessments is widely anticipated to have implications for how we interpret scores. This workbook presents a non-exhaustive list of discussion topics and questions, grouped by the topic areas discussed in the Center for Assessment's RILS webinar on Spring 2021 assessments which were based on two recent publications, "Into the Unknown: Assessments 2021," and "Restart & Recovery: Assessments in Spring 2021." SEAs can ask and answer these questions to facilitate planning and decision-making for their spring 2021 summative assessment in a way that leverages the collective expertise of those who have contributed their time and thoughtful ideas through manuscripts, presentations, and panel discussions.

Published
2020

6. Investigation of 2018 ACT Score Declines Final Report

Author

National Center for the Improvement of Educational Assessment, Inc. (NCIEA), Keng, Leslie, and Boyer, Michelle

Abstract

ACT requested assistance from the National Center for the Improvement of Educational Assessment (Center for Assessment) to investigate declines of scores for states administering the ACT to its 11th grade students in 2018. This request emerged from conversations among state leaders, the Center for Assessment, and ACT in trying to understand the 2018 score declines, particularly in census testing states. The primary goals of the Center's investigation were to: (1) identify possible explanations for the observed score declines based on information provided by ACT; (2) make recommendations to ACT and states for additional analyses to confirm or uncover explanations for the observed trends; and (3) suggest changes to ACT's existing processes or procedures that can help expedite the detection of such trends or mitigate potential sources of error in the future. The Center pursued three general lines of inquiry to understand potential contributions to the ACT score declines in 2018. This report examines: (1) ACT's established procedures; (2) implementation of its established procedures; and (3) select contextual factors related to the test-taking populations.

Published
2020

7. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

Author

Stilgenbauer, Stephan, Tausch, Eugen, Roberts, Andrew W., Davids, Matthew S., Eichhorst, Barbara, Hallek, Michael, Hillmen, Peter, Schneider, Christof, Schetelig, Johannes, Böttcher, Sebastian, Kater, Arnon P., Jiang, Yanwen, Boyer, Michelle, Popovic, Relja, Ghanim, Majd T., Moran, Michael, Sinai, Wendy J., Wang, Xifeng, Mukherjee, Nabanita, Chyla, Brenda, Wierda, William G., and Seymour, John F.

Published
2024
Full Text
View/download PDF

8. Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human StudyLong-term Outcomes of R/R NHL Pts Treated with Venetoclax

Author

Davids, Matthew S, Roberts, Andrew W, Kenkre, Vaishalee P, Wierda, William G, Kumar, Abhijeet, Kipps, Thomas J, Boyer, Michelle, Salem, Ahmed Hamed, Pesko, John C, Arzt, Jennifer A, Mantas, Margaret, Kim, Su Y, and Seymour, John F

Subjects
Rare Diseases, Lymphoma, Hematology, Cancer, Clinical Research, Antineoplastic Agents, Bridged Bicyclo Compounds, Heterocyclic, Follow-Up Studies, Humans, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Recurrence, Sulfonamides, Time Factors, Waldenstrom Macroglobulinemia, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeWe previously reported a 44% overall response rate (ORR) with the oral BCL-2 inhibitor venetoclax in a phase I study of relapsed/refractory non-Hodgkin lymphoma (NHL). Complete response (CR) was observed in patients with mantle cell lymphoma [(MCL), 21%, n = 6/28] and follicular lymphoma [(FL), 17%, n = 5/29], and partial response (PR) noted in several patients with Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL). Here, we report the long-term outcomes of these four cohorts.Patients and methodsAll patients (n = 106) received venetoclax monotherapy in dose cohorts of 200 to 1,200 mg daily until disease progression or unacceptable toxicity. ORR, progression-free survival (PFS), duration of response (DoR), and adverse events (AEs) were evaluated.ResultsAt a median follow-up of 38.5 months (range, 30.0-46.5), the median PFS for all 106 patients was 5.4 [95% confidence interval (CI), 3.5-8.4] months (FL, 10.8; MCL, 11.3; MZL, 21.2; and WM, 30.4). The median DoR was 14.9 (95% CI, 9.7-27.6) months (FL, 26.6; MCL, 15.7; MZL, 20.1; and WM, 25.3). Achievement of CR versus PR predicted longer DoR in both MCL (31.5 vs. 10.1 months) and FL (37.6 vs. 9.7 months). All grade hematologic AEs were infrequent: neutropenia (19%), anemia (19%), and thrombocytopenia (17%), with no new cytopenias after 2 years on therapy. Nonhematologic AEs included nausea (49%), diarrhea (46%), fatigue (44%), with decreased incidence after 1 year.ConclusionsVenetoclax monotherapy has a manageable safety profile and achieves durable responses in a subset of patients with FL, MCL, WM, and MZL, particularly in those who achieve CR. Further research is warranted on combination strategies to enhance the durability of response to venetoclax.

Published
2021

9. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Author

Kater, Arnon P, Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter, D’Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R, Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, and Seymour, John F

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Lymphoma, Genetics, Rare Diseases, Good Health and Well Being, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Bridged Bicyclo Compounds, Heterocyclic, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Karyopherins, Leukemia, Lymphocytic, Chronic, B-Cell, Mutation, Progression-Free Survival, Proto-Oncogene Proteins B-raf, Receptor, Notch1, Receptors, Cytoplasmic and Nuclear, Rituximab, Sulfonamides, Treatment Outcome, Tumor Suppressor Protein p53, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeIn previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine plus rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At the 4-year follow-up, we report long-term outcomes, response to subsequent therapies, and the predictive value of molecular and genetic characteristics.Patients and methodsPatients with CLL were randomly assigned to 2 years of venetoclax (VenR for the first six cycles) or six cycles of BR. PFS, overall survival (OS), peripheral-blood minimal residual disease (MRD) status, genomic complexity (GC), and gene mutations were assessed.ResultsOf 389 patients, 194 were assigned to VenR and 195 to BR. Four-year PFS and OS rates were higher with VenR than BR, at 57.3% and 4.6% (hazard ratio [HR], 0.19; 95% CI, 0.14 to 0.25), and 85.3% and 66.8% (HR, 0.41; 95% CI, 0.26 to 0.65), respectively. Undetectable MRD (uMRD) at end of combination therapy (EOCT) was associated with superior PFS compared with low MRD positivity (HR, 0.50) and high MRD positivity (HR, 0.15). Patients in the VenR arm who received ibrutinib as their first therapy after progression (n = 12) had a reported response rate of 100% (10 of 10 evaluable patients); patients subsequently treated with a venetoclax-based regimen (n = 14) had a reported response rate of 55% (six of 11 evaluable patients). With VenR, the uMRD rate at end of treatment (EOT) was lower in patients with GC than in those without GC (P = .042); higher GC was associated with shorter PFS. Higher MRD positivity rates were seen with BIRC3 and BRAF mutations at EOCT and with TP53, NOTCH1, XPO1, and BRAF mutations at EOT.ConclusionEfficacy benefits with fixed-duration VenR are sustained and particularly durable in patients who achieve uMRD. Salvage therapy with ibrutinib after VenR achieved high response rates. Genetic mutations and GC affected MRD rates and PFS.

Published
2020

10. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Author

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara F., D'Rozario, James, Owen, Carolyn J., Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Panchal, Anesh, Lu, Tong, Wu, Jenny Q., Jiang, Yanwen, Lefebure, Marcus, Boyer, Michelle, and Kater, Arnon P.

Published
2022
Full Text
View/download PDF

11. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

Author

Kersting, Sabina, Dubois, Julie, Nasserinejad, Kazem, Dobber, Johan A, Mellink, Clemens, van der Kevie-Kersemaekers, Anne-Marie F, Evers, Ludo M, de Boer, Fransien, Koene, Harry R, Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A, van der Spek, Ellen, van der Straaten, Hanneke M, Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F M, Visser, Hein P J, Houtenbos, Ilse, Idink, Cecile A M, Issa, Djamila E, Dompeling, Ellen C, van Zaanen, Henk C T, Veelken, Hendrik, Levenga, Henriette, Tick, Lidwine W, Terpstra, Wim E, Tonino, Sanne H, Boyer, Michelle, Mobasher, Mehrdad, Levin, Mark-David, and Kater, Arnon P

Published
2022
Full Text
View/download PDF

13. Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study

Author

Deng, Rong, Gibiansky, Leonid, Lu, Tong, Agarwal, Priya, Ding, Hao, Li, Xiaobin, Kshirsagar, Smita, Lu, Dan, Li, Chunze, Girish, Sandhya, Wang, Jue, Boyer, Michelle, Humphrey, Kathryn, Freise, Kevin J., Salem, Ahmed Hamed, Seymour, John F., Kater, Arnon P., and Miles, Dale

Published
2019
Full Text
View/download PDF

15. Statistically Comparing the Performance of Multiple Automated Raters across Multiple Items

Author

Kieftenbeld, Vincent and Boyer, Michelle

Abstract

Automated scoring systems are typically evaluated by comparing the performance of a single automated rater item-by-item to human raters. This presents a challenge when the performance of multiple raters needs to be compared across multiple items. Rankings could depend on specifics of the ranking procedure; observed differences could be due to random sampling of items and/or responses in the validation sets. Any statistical hypothesis test of the differences in rankings needs to be appropriate for use with rater statistics and adjust for multiple comparisons. This study considered different statistical methods to evaluate differences in performance across multiple raters and items. These methods are illustrated leveraging data from the 2012 Automated Scoring Assessment Prize competitions. Using average rankings to test for significant differences in performance between automated and human raters, findings show that most automated raters did not perform statistically significantly different from human-to-human inter-rater agreement for essays but they did perform differently on short-answer items. Differences in average rankings between most automated raters were not statistically significant, even when their observed performance differed substantially.

Published
2017
Full Text
View/download PDF

16. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

Author

Hausfater, Pierre, Pourriat, Jean-Louis, Casalino, Enrique, Riou, Bruno, Pateron, Dominique, Yéni, Patrick, Bricaire, François, Ville, Yves, Azria, Elie, Dommergues, Marc, Bergmann, Jean-François, Wolff, Michel, Mira, Jean-Paul, Guillevin, Loïc, Zuber, Mathieu, Abasse, Soumeth, Aberrane, Saïd, Abgueguen, Pierre, Abokasem, Ayman, Abraham, Bruno, Ache-Papillon, Chantal, Adam, Pascal, Adam, Marie-Noëlle, Adhoute, Xavier, Adoue, Daniel, Afi, Moncef, Afroukh, Nawel, Agha-Mir, Ilhem, Aissa, Nejla, Aissaoui, Liamine, Akerman, Grégory, Akkari, Ali, Al Chaar, Majed, Al Freijat, Faraj, Al-Jalaby, Bachar, Albert, Didier, Albertini, Marie-Thérèse, Albinet, Hélène, Alfonsi, Gwenaël, Ali, Youssef, Chaouche, Zahr-Eddine Ali, Allart, Anne, Alric, Laurent, Améri, Alain, Amoura, Zahir, Ampère, Alexandre, Amroun, Hakim, Ananivi, Amévi, Ancelin, Pascal, André, Thierry, Andremont, Antoine, Andreotti, Dominique, Andriamaneo, Hélinoro, Andriau, Clara, Anglaret, Hélène, Anguel, Nadia, Annaix, Véronique, Anteur, Wassila, Anuset, Delphine, Aoudia, Ourida, Arabi, Miloud, Archambaud, Muriel, Archambaud, Maryse, Ardiet, Emmanuel, Argaud, Laurent, Arista, Sophie, Arlet, Guillaume, Armengaud, Jean, Arnal, Jean-Michel, Arnault, Isabelle, Arsène, Olivier, Assaf, Ziad, Assi, Assi, Assouline, David, Astruc, Dominique, Aubard, Yves, Aubert, Claude, Aubry, Jean-Paul, Auburtin, Marc, Aucher, Philippe, Audeguy, Philippe, Audié, Jean-Pierre, Aumaitre, Hugues, Aumersier, Michel, Auroux, Jean, Autret, Fanny, Auvray, Etienne, Ayach, Badih, Aye, Paul, Ayouz, Khélifa, Bachelier, Marie-Nadège, Badia, Thomas Bachelot Philippe, Badila, Patrice, Bador, Julien, Badurescu, Viorica, Baldesi, Olivier, Bandaly, Françoise, Bandin, Olivia, Bani-Sadr, Firouzé, Bannier, Stéphanie, Baranger, Thierry, Barazer, Isabelle, Barbier, Marie-Christine, Barbier, François, Barbier, Carole, Barbieux, Marianne, Marie, Barboteau, Annick, Barbut, Patricia, Baret, Mylène, Barière, François, Baril, Jean-Yves, Barillot, Isabelle, Barjon, Geneviève, Barnaud, Guilène, Barraduc, Régine, Barraud, Francis, Barraud, Olivier, Barre, Eric, Barrelet, Audrey, Barrier, Jocelyn, Bart, Fréderic, Barthélémy, Gérard, Baty, Gaëlle, Baud, Olivier, Baudel, Jean-Luc, Bay, Jacques-Olivier, Bay, Jérôme, Bazin, Claude, Beague, Sébastien, Beal Ardisson, Dominique, Beaune, Bertrand, Beauplet-Lepage, Anne, Bébéar, Cécile, Bechade, Dominique, Becherrawy, Céline, Becker-Schneider, Michelle, Bednarek, Nathalie, Bedock, Bernard, Begon, Edouard, Bekguesmia, Zaineb, Belaisch-Amart, Joëlle, Belhadj, Karim, Belle, Evelyne, Belmonte, Olivier, Belot, Jean-Pierre, Bemrah, Abdelkader, Ben Soltana, Mouna, Benbara, Amélie, Benddif-Fin, Faiza, Bénézit, François, Benifla, Jean-Louis, Benjelloul, Amine, Benkaci, Yacine, Benkhelil, Abdelaziz, Benoit-Cattin, Thierry, Benoit-Coustou, Sophie, Bensadoun, René-Jean, Bensaid, Thierry, Jacques Bensaude, Raoul, Bérard, Henri, Bercot, Béatrice, Berdin, Bruno, Berger, Marc, Berger, Pierre, Bergheul, Smail, Bergues, Benoît, Berland, Yvon, Bernard, Claude, Bernard, Louis, Bernardaud, Bérangère, Bernardi, Franck, Bernardin, Gilles, Bernasconi, François, Bert-Marcaz, Patrick, Berteaux, Béatrice, Berth-Farges, Anne, Berthelot, Gilles, Berthet, Jean, Bertrand, Kevin, Bertrou, Anne, Besnard, Marianne, Bessede, Emilie, Bethery, Philippe, Beuscart, Claude, Beyne-Rauzy, Odile, Beytout, Jean, Bezian, Marie-Christine, Bicais, Brigitte, Bidart, Sabine, Bidault, Christian, Biessy, Hélène, Bigot, Pierre, Bildea, Adrianna, Bille, Emmanuelle, Billy, Christophe, Biron, Nathalie, Bizet, Jérôme, Blaise, Didier, Blaise, Agathe, Blaison, Gilles, Blaka, Mariam, Blanc, Pierre, Blanc, Stéphane, Blanc-Amrane, Véronique, Blanchard, Pierre, Blanchard-Marche, Geneviève, Blancs, Michèle, Blazejewski, Caroline, Bléher, Yves, Blewoussi, Koffi, Blondet, Romain, Blot, François, Blum, Georges-Fabrice, Bodson, Lucien, Boidin, Emilie, Boileau, Julien, Boileau, Pascal, Boin-Gay, Véronique, Boisseau, Martial, Boisselier, Christine, Bollaert, Pierre-Edouard, Bolot, Pascal, Bonacorsi, Stéphane, Bonfils, Marie, Bonitchi, Pascal, Bonnan, Mickael, Bonnefoy, Philippe, Bonnet, Delphine, Bonnet, Richard, Bonnin, Emmanuelle, Bor, Jacques, Borie, Marie-Françoise, Borstein, Bernard, Bossi, Philippe, Botreau, Yves, Bottero, Julie, Bouasria, Abderrezak, Bouaziz, Radia, Bouchaud, Olivier, Bouche, Flore, Bouchet, Gérard, Bouden, Vincent, Boudhane, Amar, Boudy, Carole-Anne, Boue, François, Bouet, Cédric, Claude Boufetteau, Jean, Bouffandeau, Bernard, Bouhour, Damien, Bouiller, Marc, Bouillet, Laurence, Bouissou, Antoine, Boulain, Luc, Bourgeois, Stéphane, Bourgerette, Evelyne, Bourlet, Anne, Bourlière, Marc, Bourrée, Thomas, Bourrouillou, Aude, Boussekey, Nicolas, Boussier, Remi, Boutoille, David, Bouyer, Jean-Luc, Bouyssou-Destriau, Denise, Bouziges, Nicole, Boyer, Michelle, Braem, Louis, Branger, Bernard, Branger, Catherine, Brasme, Lucien, Bray, Philippe, Brazille, Patricia, Bresson, Violaine, Bret, Laurent, Breton, Anne-Laure, Breuil, Jacques, Brevet, Françoise, Briaud, Michel, Bridoux, Delphine, Briend, Delphine, Briere, Anne-Isabelle, de la Hosseraye, Claire Briere, Brieu, Nathalie, Brieux, Jean-Philippe, Brihier, Hélène, Brisou, Patrick, Brival, Marie-Laure, Broche, David, Brochen, Joëlle, Bron, Camille, Bronet, Nathalie, Bronner, Jacques, Bronowicki, Jean-Pierre, Brosset, François, Brottier-Mancini, Elisabeth, Brovedani, Sophie, Bruley des Varannes, Stanislas, Brunel, Pascale, Brunet, Patrick, Brunet, Xavier, Brunet, Stéphanie, Brung-Lefebvre, Maud, Brunot, Vincent, Brusset, Alain, Burc-Struxiano, Laurence, Burdin, Michèle, Bureau, Thierry, Buron, Fanny, Burucoa, Christophe, Cabalion, Jean, Cabasson, Severine, Cabié, André, Cacheux, Victoria, Cadiergue, Vincent, Cadiot, Guillaume, Caille, Vincent, Cailleaux Pierre-Etienne Cailleux, Vincent, Caillon, Jocelyne, Caillot, Denis, Camara, Mohamed, Cambau, Emmanuelle, Cambonie, Gilles, Camiade, Sabine, Canis, Frederique, Canitrot, Meriem, Canu, Nathalie, Capellier, Gilles, Carbillon, Lionel, Carbonelle, Bernard, Carbonelle, Etienne, Carboni, Marion, Carbonne, Bruno, Carcenac, Francis, Cardot, Florence, Carette, Sylvie, Cariou, Sylvie, Carli, Pierre, Carmagnol, Françoise, Caroli-Bosc, François-Xavier, Caron, François, Cartron, Guillaume, Casali, Patrick, Casanovas, Olivier, Cassignard, Dominique, Castaing, Denis, Castel, Brisse, Castelin, Sandrine, Castelnau, Pierre, Cathebras, Pascal, Catineau, Jean, Catteu, Sylviane, Cattier, Blandine, Cattoen, Christian, Cattoir, Vincent, Caumes, Eric, Caussin, Jean, Cavalié, François, Ceppa, Franck, Cerf, Charles, Ceriez, Anne, Cervantes, Nathalie, Chabanon-Pouget, Bruno, Chabrol, Amélie, Chachaty, Elisabeth, Chahtour, Hanen, Chaix, Fabrice, Challier, Marion, Chalvon-Demersay, Arnaud, Chambreuil, Guy, Chaminade, Bruno, Chamouine, Abdourahim, Chandesris Joséphine Chapalain-Cagnon, Christine, Chapelle, Alain, Chaplain, Chantal, Chapuzet, Claire, Charachon, Sylvie, Charasse, Christophe, Charbonnier, Thierry, Charlier, Franck, Chassin, Olivier, Chassy, Véronique, Chatellier, Delphine, Chatron, Marlène, Chaussade, Hélène, Chavanet, Pascal, Chavel, Pascale, Chekroun, Ali, Chelle, Wladimir, Chelly, Jonathan, Cherlet, Christel, Chevailler, Alain, Chevalet, Pascal, Chevalier, Yannick, Chidiac, Christian, Chimot, Loïc, Chiouk, Nabil, Chiron, Philippe, Chirouze, Catherine, Chopin, Marie-Charlotte, Choukroun, Gabriel, Chouraqui, Martine, Chraibi, Kamilla, Chudersky, Dominique, Chuzeville, Michel, Cingotti, Michel, Cinquetti, Gael, Ciocan, Dragos, Citony, Isabelle, Claise, Catherine, Clarissou-Philippe, Juliette, Claude, Benoît, Clave, Danielle, Clément, Christophe, Climas, Marie-Thérèse, Coetmeur, Daniel, Cognet, Stéphanie, Cohen, Daniel, Coignard, Sophie, Coindre, Jean-Philippe, Coint, Raphaël, Colamarino, Renato, Colingorski, Anne-Marie, Collard, Olivier, Collet, Michel, Collignon, Anne, Collus, Marie-José, Colombani, Jean-Claude, Colombat, Philippe, Combe, Christian, Condominas, Philippe, Conroy, Marie-Chrsitine, Constans, Thierry, Constantin, Nicole, Contamin, Claudine, Corberand, Damien, Cordier, Anne-Marie, Cordonnier, Charlotte, Corneloup, Hélène, Costa, Yannick, Costa, Frédérique, Coste, Mathieu, Costes, Corinne, Cotes, Françoise, Cotteret, Rabea, Couderc, Louis-Jean, Cougoul, Pierre, Coulaud, Jean-Michel, Coulhon, Marie-Pierre, Coulon, Patrice, Courcol, René, Courillon, Florence, Courjon, Johan, Courouble, Jérémie, Courouge-Dorcier, Dominique, Courtade, Henri, Courtois, Stéphanie, Couturier, Pascal, Créange, Alain, Cremet, Lise, Cremniter, Julie, Croize, Jacques, Crombe, Valérie, Croquet, Ingrid, Cua, Eric, Cufi, Marie-Noelle, Cuvillier, Patrice, Dabysing, Marie-Françoise, Dadoun, Karim, Dagada, Corinne, Dahan, Sonia, Dahoumane, Redouane, Daleas, Jacques, Dallay, Dominique, Dalle, Benoît, Damage, Alexandre, Damaj, Lena, Damaj Gandhi, Laurent, Danalaché, Ana, Danin, Pierre-Eric, Danjean, Marie-Pierre, Danquechin Dorval, Etienne, Dao, Anne, Daoud, Patrick, Darchen, Olivier, Dargère, Sylvie, Darre, Bincy, Dassant, Damien, Dassieu, Gilles, Dattin-Dorrière, Valérie, Daupin, Cedric, Daurel, Claire, Dausset, Jean-Claude, Daval Cote, Mélanie, David, Gary, Davido, Benjamin, De Barbeyrac, Bertille, De Biasi, Michel, De Boysson, Hubert, De Clareuil, Edith, De Kermadec, Jean-Michel, De Martino, Sylvie, De Tayrac, Renaud, De Varax, Roland, De Witte, Sten, Debernardi, Anne, Deboutin, Jean-Luc, Debouverie, Marc, Decoene, Christophe, Decoster, Anne, Decousser, Jean-Winoc, Decré, Dominique, Defebvre, Renaud, Degand, Nicolas, Degreff, Jean-Marc, Deiber, Michel, Delaby, Hélène, Delacour, Thierry, Delahaye, Arnaud, Delarbre, Jean-Marie, Delasalle, Chantal, Delbrouck, Claire, Delecalle, Jean-Gilles, Delesalle, Sophie, Delesalle, Chantal, Delhoustal, Laurence, Deligne, Delphine, Delisle Mizon, Françoise, Delobel, Pierre, Delour, Pierre, Delpeuch, Bruno, Demachy, Marie-Claude, Demarchi, Martin, Demarcq, Marie-Joelle, Demontclos, Henri, Dengo, Jean-Christophe, Deprecq, Sophie, Dequin, Pierre-François, Dereeper, Olivier, Deroux, Alban, Derragui, Aicha, Desblache, Julien, Desbois-Nogard, Nicole, Descamps, Dominique, Descamps, Jean-Michel, Deschamps, Christophe, Deschamps, Jacques, Desemerie, Franck, Desfrere, Luc, Desliers, Joelle, Desnoulez, Laurence, Desplaces, Nicole, Després, Nicolas, Dessin, Jean-François, Destors, Marie, Detante, Olivier, Detave, Mathieu, Detourmignies, Laurence, Devaud, Edouard, Devaux, Yves, Devaux, Bruno, Devianne, François, Devidas, Alain, Devos, Philippe, Dewitte, Camille, Dewulf, Gisèle, Dhennain, Chantal, Di Meglio, Chloé, Diallo, Habiboulaye, Diamantis, Sylvain, Dib, Baihas, Didier, Jean-Marc, Dillies, Anne-Françoise, Dingremont, Claire, Djafari, Noureddine, Djeffal, Abdelmajid, Djerad, Hama, Dollon, Christophe, Doloy, Alexandra, Domart, Yves, Donay, Jean-Luc, Dopeux, Loïc, Dorr, Gaelle, Doucet Populaire, Florence, Dournon, Nathalie, Dreyfus, Michel, Dreyfuss, Didier, Du Cheyron, Damien, Dubois, Elodie, Dubois, Nicolas, Dubosc-Marchenay, Nadine, Dubourdieu, Béatrice, Dubroca, Nadine, Dubus, Jean-Christophe, Duche, Catherine, Duchene, Francis, Dudeffant, Patrick, Duez, Jean-Marie, Duhaut, Pierre, Duluc, Françoise, Dumouchel, Hélène, Dumoulard, Bruno, Dupin, Clarisse, Dupon, Michel, Dupont, Mathieu, Dupont, Damien, Dupont, Patrick, Dupre-Narlet, Emmanuelle, Dupretz, Peggy, Dupuy, Claire-Antoinette, Durand, Michel, Durand, Annie, Durliat-Ellie, Solène, Durox, Hélène, Dussopt, Christine, Dutasta, Fabien, Duval, Véronique, Dzeing, Ella, Eboue, Florence, Ede, Cyrille, Eid, Hanna, El Yamani, Abderrazak, Elbez, Annie, Eldeghedy, Mohamed, Elena-Daumas, Martine, Elhadad, Simon, Elharie-Heraux, Zoubida, Eloy, Clarence, Emeriau, Marie-Etiennette, Emond, Jean-Philippe, Equy, Véronique, Erena-Penet, Anne-Sophie, Esnault, Cecilia, Esposito, Laure, Essouri, Sandrine, Estépa, Laurence, Estève, Vincent, Etchemendy, Sabine, Ettahar, Nicolas, Eustache, Marie-Line, Evillard, Mathieu, Evreux, Françoise, Eychene, Jean-Marc, Eyer, Didier, Eymerit, Philippe, Fabre, Jean-Luc, Fabre, Claire, Faibis, Frédéric, Falchero, Lionel, Falguières, Odile, Fallouh, Hassan, Fanjaud, Nicolas, Fantin, Bruno, Farah, Ibrahim, Farto-Bensasson, Fernanda, Fauchais, Anne-Laure, Fauchart, Jean-Pierre, Faucher, Anna, Faucheux, Jean-Marc, Faudon-Gibelin, Anne, Faurie, Pierre, Fèbre, Claudine, Feddal, Toufik, Ferhat Carre, Assia, Ferreira-Maident, Nicole, Ferreyra, Milagros, Ferroni, Agnès, Ferry, Tristan, Feugier, Pierre, Feugier, Jean-Claude, Fezoui, Hacene, Fiette, Hélène, Fille, Alexandra, Filloux, Jean-Michel, Fily, Fabien, Fines, Marguerite, Fissore Magdelein, Cristel, Flahault, Mathilde, Floriot, Christian, Foguem, Clovis, Fonsale, Nathalie, Fontenel, Benoît, Forest, Anne-Marie, Forest, Anne, Forestier, Emmanuel, Fortin, Louise, Fortineau, Nicolas, Fos, Marie-Pierre, Foucart, Saskia, Fouilhoux, Alain-Charles, Fournel, Pierre, Fournier, Damien, Fourrier, François, Fraisse, Thibaut, Fredenucci, Isabelle, Fremin-Batteux, Odile, Frey, Janine, Frimat, Luc, Froidure, Marie, Fruchart, Christophe, Fruleux, Nathalie, Fuhrmann, Christine, Fuillet, Michel, Funakoshi, Nathalie, Fur, Alain, Gabez-Therou, Patricia, Gaborieau, Valerie, Gabriel-Soléan, Sylvie, Gachassin, Laurence, Gaide, Jean-François, Gaillard, Julia, Gaillard, Jean-Louis, Gaillart, Tiphaine, Gaizi, Sad, Gallo, Nicolas, Gameiro, Manuel-Luis, Garandeau, Caroline, Garbi, Aurelie, Garcera, Yves, Gardes, Ghislaine, Garesslin, Olivier, Garnier, Fabien, Garofano, Marie, Garosi, Olivier, Garre, Michel, Garrec, Hélène, Garrigues, Bernard, Gaschet, Anne, Gascon, Alexandre, Gascou, Emmanuel, Gasnault, Jacques, Gatfosse, Marc, Gattault, Jean-François, Gatti, Hélène, Gauche, Bernard, Gaudard, Philippe, Gaudelus, Joel, Gaudry, Stéphane, Gauduchon, Valérie, Gaulthier, Jean-Baptiste, Gauthier, Yvan, Gebeile, Rémi, Geffray, Loïc, Geffroy, Françoise, Geissler, Alain, Gelez, Maud, Gendrin, Vincent, Gengembre, Guy, Gentilhomme, Hervé, Gérart Pons, Sandrine, Germain, Marie-Claude, Gesquière, Julien, Ghedira, Adel, Ghevaert, Christine, Gillot, Jean-Michel, Girard, Edouard, Girard, Serge, Girard, Pierre-Marie, Girard-Buttaz, Isabelle, Giraud, Martine, Glorieux, Isabelle, Goburdhun, Chandrah, Godin, Michel, Godon, Catherine, Goehringer, François, Goffart, Sylvie, Goidin, Isabelle, Goldgran Toledano, Daniele, Golfier, François, Goll, Armand, Gontieron, Olivier, Goquelin, Anne, Got, Laurence, Goudeau, Alain, Goujard, Cécile, Goupil, François, Gouraud, François, Gourlaouen, Alain, Gournay, Jérôme, Goustille, Julien, Goux, Alain, Grandclerc, Benoît, Grange, Jean-Didier, Granger, Thierry, Granier, Françoise, Granier, Michèle, Grasset, Denis, Gravet, Alain, Grawey, Isabelle, Greder Belan, Alix, Grelaud, Jean-Jacques, Grenet, Karine, Gressier, Bernard, Grignon, Bernadette, Grimprel, Emmanuel, Grise, Geneviève, Grobost, Vincent, Gross Goupil, Marine, Grossi, Olivier, Gruffat, Brigitte, Gruson, Anne, Guénard, Yves, Guérard, Arnaud, Guérin, Bruno, Guérin, Mathilde, Guérin, Claude, Guerquin, Bernard, Guerrot, Dominique, Guéry, Benoît, Gueudet, Philippe, Gueugniaud, Pierre-Yves, Guichard, Isabelle, Guichart, François, Guiden, Ozel, Guider, Bertrand, Guillarmé Grossmann, Pascale, Guillemot, François, Guillet, Pierre, Guillet-Caruba, Christelle, Guillois, Bernard, Guilloy, Olivier, Guimard, Thomas, Guimard, Karine, Guimier, Philippe, Guinard, Jérôme, Guinet, François, Guisset, Olivier, Guitteaud, Karine, Gutmann, Laurent, Guyetand, Severine, Haccourt, Fabian, Hacot, Jean-Pierre, Hadou, Tahar, Haiat, Stéphanie, Haioun, Corinne, Hajjar, Mostapha, Hamitou, Zakaria, Hammami, Sarah, Hamon-Charles, Sophie, Hamou-Plotkine, Laurence, Hanouz, Jean-Luc, Harbi, Samia, Harlé, Jean-Robert, Haro, Sophie, Harou, Christian, Harvey, Thierry, Hatem, Ghada, Hausermann, Marie-Hélène, Hauss, Pierre-Alexandre, Hayoun, Fabrice, Hecham, Moussa, Heches, Xavier, Hedjem, Nourredine, Heidt, Anne, Heisel, Nicolas, Heluwaert, Fréderic, Helvadjian, Thierry, Henni, Tawfiq, Henry-Andrieu, Yanne, Hequet, Delphine, Herbecq, Patrick, Herbrecht, Raoul, Hernu, Romain, Herry, Catherine, Herry, Jean-Paul, Herson, Serge, Heurtaux, Marie-Noelle, Heusse, Emmanuelle, Heyraud-Blanchet, Catherine, Hichri, Yoar, Hilbert, Gilles, Hili, Marie-Thérèse, Hiret, Sandrine, Hittinger, Gilles, Hochart, Anne-Cécile, Hodee, Nathalie, Holstein, Anne, Hombrouk-Alet, Cécile, Hominal, Stéphane, Honderlick, Patrick, Honoré Bouakline, Stéphanie, Hory, Bernard, Hourdebaigt-Larrusse, Pierre, Houssaye, Serge, Houssiaux-Maisonneuve, Nathalie, Hrichi, Abdelkader, Hubert, Didier, Huc, Benoît, Humbert, Karine, Hurel, Dominique, Husson-Wetzel, Stéphanie, Hutin, Pascal, Huttin, Bernard, Hyerle, Laura, Iacobelli, Silvia, Ilunga, Serge, Imbert, Guenièvre, Jabre-Sikias, Elias, Jacob, Jean-Louis, Jacobs, Romain, Jacomy, Dominique, Jacquier, Pascal, Jacquier, Hervé, Jaffarbandjee, Marie-Christine, Jamet, Angéline, Jan, Didier, Jang, Guyro, Jaouen, Anne-Christine, Jardel, Henry, Jarlier, Vincent, Jarrige, Luc, Jarrousse, Bernard, Jauhlac, Benoît, Jault, Véronique, Jault, Thierry, Jaunait, Eric, Javouhey, Etienne, Jean, Rodolphe, Jean, Julie, Jean-Pierre, Hélène, Jeanmaire, Eliette, Jeannot, Katy, Jeddi, Hassen, Jego, Mickael, Jennane, Selim, Join-Lambert, Olivier, Joly, Pascal, Jonquet, Olivier, Josien, Eric, Jouatte, Fabienne, Jouffret, Agnès, Jourde-Chiche, Noémie, Jourdes, Emilie, Jouvencel, Philippe, Jouzel, Charlotte, Julienne, Geneviève, Jullian, Eric, Juven, Agnès, Juvin, Philippe, Kaidomar, Michel, Kaiser, Thomas, Kalfon, Pierre, Kaltenbach, Georges, Kamar, Nassim, Kansau, Imad, Kara, Ali, Karaoui, Leila, Karirisi, Apollinaire, Karkous, Bernard, Kassis, Marie, Kayal, Samer, Keller, Marie, Kemenar, Chrystelle, Kennouche, Samir, Kerchache, Aissa, Kerleau, Jean-Marc, Kervegant, Anne-Gaelle, Khalifa-Thellier, Sandrine, Radhouane-Khanjari, Fethi, Kherouf, Hakim, Khodeir, Nordine, Kibbrecht, Eric, Kim, An, Kisterman, Jean-Paul, Kittschke, Bernard, Klapczynski, Frédéric, Kodzin, Marie-José, Konate, Bano, Kouaho, Sylvain, Koulmann, Laurence, Krechiem, Karim, Kubab, Sarah, Kubiak, Charles, Kurtz, Jean-Emmanuel, Labadie, Philippe, Labarrière, Damien, Labaune-Kiss, Andrea, Labé, Aurélie, Labourdette, Isabelle, Labrousse, Philippe, Labussière, Anne-Sophie, Lachenal, Florence, Lacroix, Jérôme, Lafeuillade, Alain, Lafforgue, Marie-Odile, Lafon, Ingrid, Lagasse, Jean-Pierre, Lagrandeur, Julien, Lalot, Jean-Marc, Lalu, Mélissa, Laluque, Simone, Lamache, Sébastien, Lamarca, Richard, Lamberet, Aurore, Lambert, Thierry, Lambiotte, Fabien, Lamia, Bouchra, Lamoine-Gimet, Ghislaine, Lamour, Armelle, Lamy, Brigitte, Lanba, Patrice, Landgraf, Nathalie, Landraud, Luc, Laporte, Jean-Patrick, Larible, Claire, Larrazet, Fabrice, Larroche, Claire, Lasbasses, Claudine, Lassel, Ludovic, Lassere, Bertrand, Laudat, Patrice, Lauque, Dominique, Laurens, Etienne, Laurent, Frédéric, Lauretta, Raphael, Laurin, Max, Lauzanne, Brigitte, Lavalard, Emmanuelle, Lavenu, Isabelle, Lavigne, Jean-Philippe, Le Baron, François, Le Berre, Rozenn, Le Berruyer, Pierre-Yves, Le Bideau, Marc, Le Boterff, Cécile, Le Chevallier, Sylvain, Le Coustumier, Alain, Le Du, Anne, Le Goff, Valérie, Le Henaff, Catherine, Le Lay, Geneviève, Le Maout, Gilles, Le Pierres, Athéna, Le Pimpec, Patricia, Le Poulain, Marguerite, Le Reste, Anne-Marie, Le Sec, Ludovic, Le Turdu, Françoise, Leautez-Nainville, Sophie, Lebas, Eddy, Leblond, Véronique, Lebreton, Marie-Annick, Lebreton, Didier, Lecaillon-Thibon, Evelyne, Lechat, Sylvie, Lechiche, Catherine, Lecis, Alain, Leclercq, Roland, Lecomte, Claire, Lécuyer, Hervé, Ledru, Sylvie, Leduc, Dominique, Leflon, Véronique, Lefort, Christine, Lefranc, Hélène, Lefrant, Jean-Yves, Legendre, Christophe, Legoff, Isabelle, Legout, Laurence, Legrand, Mathieu, Legras, Annick, Legros, Antoine, Leguen, Virginie, Leibinger, Franck, Lelièvre, Jean-Daniel, Lellouche, Franck, Lemaignen, Adrien, Lemarie, Romain, Lemble, Chantal, Lemenand, Olivier, Lemercier, Fanny, Lemery, Didier, Lemmens, Bruno, Lemyze, Malcolm, Leneveu, Michel, Léonetti, Françoise, Léonnet, Caroline, Léotard, Sophie, Lepeletier, Didier, Lepelletier, Didier, Lepeule, Raphael, Lepiller, Quentin, Lequen, Laurence, Leroux, Lionel, Leroux, Stéphane, Leroy, Hélène, Leroy, Vincent, Leroy, Olivier, Lesage, Fabrice, Lescat, Mathilde, Lesecq, Ludovic, Lessene, Aude, Lessinger, Jean-Marc, Letellier, Claire, Letellier, Nicolas, Letouzey, Vincent, Letranchant, Lorraine, Levast, Marion, Leveneur, Yann, Levent, Thierry, Levy, Marie, Levy, Marc, Leysenne, David, Libeau, Benoît, Likose, Ebutu, Lima, Suzanne, Lina, Gérard, Lioger, Bertrand, Lionnet, Benoît, Lipovac, Anne-Sophie, Loffeier, Vincent, Loison, Françoise, Lorchleac'h, Aurélien, Lorge, Fabienne, Loriferne, Jean-François, Lorléa'ch, Aurélien, Louart, Guillaume, Loury-Lariviere, Isabelle, Loustaud, Véronique, Lozniewski, Alain, Luciani, Roger-Charles, Luminitan Elena Lupean, Luca, Lureau, Pierre, Lutz-Murphy, Marie-France, Mbimba, Luwawu, M'Bey, Damien, Maakaroun, Abdallah, Macci, Valérie, Magdoud, Fatma, Mager, Guy, Magna, Théophile, Magny, Jean-François, Mahaza, Chetaou, Mahé, Isabelle, Maillard, Christine, Maillet, Jean-Jacques, Maillet, François, Maillez, Sébastien, Maillot, François, Maisonneuve, Antoine, Makdessi, Solène, Malbrunot, Claire, Malbruny, Brigitte, Malderet, Caroline, Malfuson, Jean-Valère, Malherbe, Philippe, Malherbe, Patrick, Malhiere, Sophie, Mandelbrot, Laurent, Mandin, Laurent, Mandjee, Aziza, Manéglier, Benjamin, Mansouria, Mohammed, Marcu, Elena, Mariette, Jean-Bernard, Mariette, Sylvie, Markarian, Jacques, Marmouset, Carole, Marpeau, Olivier, Marret, Olivier, Marsepoil, Thierry, Marterl-Lafay, Isabelle, Martha, Benoît, Marthelet, Patrick, Martin, Xavier, Martin, Florence, Martin, Pierre, Martin, Régine, Martin, Christian, Martin Lefèvre, Laurent, Martineau, Olivier, Martinet, Olivier, Martinez, Valérie, Martinot, Martin, Martres, Pascale, Marty, Sophie, Marty-Ane, Charles, Marzouk, Paul, Mascade, Géraldine, Masia, Florent, Masseron, Thierry, Masson, Loïc, Masson, Philippe, Matheron, Isabelle, Matica, Slavius, Matray, Olivier, Mattei, Marie-Françoise, Maubert, Bertrand, Maugein, Jeanne, Maureira, Juan-Pablo, May, Thierry, May, Adrien, Maze, Vincent, Meaudre Desgouttes, Eric, Mebazaa, Alexandre, Mechai, Frédéric, Medeau, Virginie, Megbemado, Richard, Mehri, Mona, Mein-Bottini, Myriam, Melis, Adrien, Mellier, Joelle, Ménager, Philippe, Ménard, Céline, Mendes-Martin, Lucile, Menguy, Anne-Claude, Menouar, Mohamed, Merabet, Taoufik, Mercury, Paul, Meregnani, Corinne, Mérigot, Philippe, Mermont, Sylvain, Merrouche, Yacine, Merville, Pierre-Gilles, Mesnage, Renaud, Mesnard, Louis, Messager, Aurélie, Messiaen, Thierry, Messika, Jonathan, Messner Pellenc, Patrick, Métenier, Hervé, Metton, Pierre, Meyer, Christian, Mialon, Michel, Miatello, Jordi, Michaud-herbst, Alban, Michault, Alain, Micheli, Sophie, Michon, Jocelyn, Baptiste Michot, Jean, Mielczarek, Severine, Mignart, Sophie, Mignaut, Virginie, Migraine Bouvagnet, Audrey, Mihout, Fabrice, Mille, Catherine, Millet, Olivier, Milpied, Noel, Mimoz, Olivier, Minet, Jacques, Minguet, Bertrand, Mohty, Mohamad, Moiton, Marie-Pierre, Monarchi, Richard, Monceau, Yannick, Monchi, Mehran, Monlun, Eric, Monsegu, Jacques, Montagne, Nathalie, Montcriol, Ambroise, Montmasson, Bernard, Mootien, Paramasiven, Moquet, Olivier, Morando, Virginie, Moreau, Anne-Sohie, Morel, Yves, Morelon, Emmanuel, Morin-Fatome, Armelle, Morincomme, Mathieu, Morlat, Philippe, Mosser, Laurent, Motard-Picheloup, Annie, Mottaz, Philippe, Moulinoux, Claire, Mouly, Laurence, Mourad, Georges, Mouries, Jean-Claude, Moussa, Hecham, Moustache, Audrey, Muir, Jean-François, Murbach, Valérie, N'guyen, Yohann, N'guyen, Jean-Claude, N'guyen-Khac, Florence, Nabholtz, Jean-Marc, Naceur, Tarik, Nakhleh, Jean, Nare, Aline, Nassif, Xavier, Nathan-Bonnet, Frédérique, Negrery, Huguette, Negrier, Claude, Neri, Dominique, Nesrine, Hakima, Neuwirth, Catherine, Ngami, Eugène, Carole Ngo Bell, Elisabeth, Nicobaharaye, Dieudonné, Nicolet, Laurent, Nicolet, Laurence, Nicolino, Marc, Niel, Philippe, Nikodijevic, Karine, Nkunzimana, Jean-Marie, Noel, Christian, Noirot, Alain, Noto, Philippe, Noulard, Marie-Noelle, Ntalu Nkato, Christophe, Nyunga, Martine, Obiols, Julien, Ochocki, Patrick, Odent, Sylvie, Olivier, Brigitte, Oliviero, Gérard, Ondze, Basile, Orléva, Oléna, Orode, Paul, Osman, Henri, Oswald, Eric, Otean, Paola, Ouazir, Abderkader, Ozanon, Christophe, Paccalin, Marc, Pages, Marie-Christine, Paindaveine, Bénédicte, Pangon, Béatrice, Pannecouck, Jean-Marie, Paquet, Jean-Christophe, Parent, Sabrina, Parisi-Duchene, Elisabeth, Pasche, Jérôme, Pasdeloup, Thierry, Patin, David, Patrigeon, René-Gilles, Patry, Isabelle, Paul, Jean-Gabriel, Pavel, Simona, Pavic, Michel, Pawlotsky, Jean-Michel, Payan, Christopher, Payen, Christiane, Péan, Yves, Péchinot, Frédérique, Péchinot, André, Pecquet, Matthieu, Pélaquier, Agnès, Peltier, Hervé, Penn, Pascale, Pennaforte, Jean-Loup, Perez, Didier, Périsson, Caroline, Perotin, Dominique, Perouse de Montclos, Michèle, Perreve, Sophie, Perronne, Christian, Perrotin, Dominique, Pesque, Valerie, Pestel-Caron, Martine, Pestre, Vincent, Petassou, Fabrice, Petit, Marie-Cécile, Petit Hoang, Camille, Petitjean, Philippe, Pettinelli, François, Peultier, Anne-Sophie, Piala, Jean-Marie, Pialoux, Gilles, Piau, Caroline, Picard, Aurélia, Picaud, Jean-Charles, Pichard, Eric, Pierre, Martin, Pierre, Fabrice, Pierrot, Paul, Piet, Emilie, Piffaut, Marie-Claude, Pigeon, Bertrand, Pignon, Carole, Pinon, Georges, Piquet, Jacques, Piriou, Vincent, Placidi, Eric, Plainfosse, Gillles, Plane, Christophe, Plantier, Isabelle, Claudiu-Plesa, Nicolai, Plésiat, Patrick, Plessis, Patrick, Plouzeau-Jayle, Chloé, Ploy, Marie-Cécile, Pochmalicki, Gilbert, Pofelski, Joanna, Poinsignon, Yves, Poirier, Anne-Sophie, Poitevin, Françoise, Pommier, Christian, Ponceau, Bénédicte, Poncelet, Christophe, Pop, Daniela, Porcheron, Martine, Pordes, Réginald, Porthault, Eric, Portneuf, Marc, Pottier, Anne, Pouedras, Pascal, Poulain, Jocelyne, Poulain, Gérard, Poupet, Hélène, Pouyanne, Julien, Pouzoullic, Marie, Poyart, Claire, Pozzetto, Bruno, Prazuck, Thierry, Pressac, Dominique, Prévost, Fabrice, Prince, Sylvie, Priollet, Pascal, Proost, Olivier, Protar, Daniel, Pujade Lauraine, Eric, Pujol, Antoine, Puybasset, Louis, Puyhardy, Jean, Quentin, Vincent, Quinsat, Denis, Rabier, Valérie, Radaoui, Fouzia, Radenac, Florian, Radenne, Sylvie, Raffenot, Didier, Raffi, François, Rahmani, Hassène, Ramanantsoa, Céline, Ranchon, Guillaume, Ranta, Dana, Raoult, Didier, Rasigade, Jean-Philippe, Rassiat, Emmanuel, Raulin, Olivia, Ravaud, Alain, Ravet, Nathalie, Razafimahefa, Hasinrina, Razafimahery, Mirana, Re, Daniel, Real, Philippe, Rebattu, Paul, Rebeyrotte, Catherine, Reboul, Pascal, Reboux, Anne-Hélène, Recule, Christine, Redonnet, Jean-Philippe, Redor, Alexis, Regouby, Yves, Rémy, Claude, Renard, Gisèle, Renard, Benoît, Renou, Frédéric, Repellin, Philippe, Reveil, Jean-Claude, Revel, Valérie, Reverseau, Anne, Revest, Mathieu, Rey, Philippe, Rey, Hyacine, Rey Zermati, Jany, Reyes Ortega, Guillermo, Reynaud, Alain, Reynes, Jacques, Rezgui, Nasseur, Riahi, Jacques, Ribes, David, Ribier, Arnaud, Richard, Christian, Richardin, Florence, Riche, Agnès, Richette, Pascal, Ridah, Khalid, Riegel, Philippe, Riehl, Frédéric, Rigaux, Françoise, Rioux, Christophe, Rival, Gilles, Rivière, Brigitte, Robert, Henri, Robert, René, Robillard, Pierre-Yves, Roblin, Mélanie, Roblot, Pascal, Roblot, France, Rogeaux, Olivier, Roger, Pierre-Marie, Rohmer-Heitz, Dominique, Rolland, Christophe, Roncato-Saberane, Mariam, Ronda, Isabelle, Rondepierre, Philippe, Roque-Afonso, Anne-Marie, Rosay, David, Rose, Christian, Roseau, Jean-Baptiste, Rosello, Sophie, Rosselli, Sylvène, Rossignol, Serge, Rostaing, Lionel, Roth, Christian, Rothe, Marie-Rose, Roubert, Xavier, Rouget, Sébastien, Rouidi, Ahmed, Roulier, Philippe, Rouquet, Yannick, Rouquette-Vincent, Isabelle, Roure Sobas, Chantal, Rousseau, Sylvaine, Rousseau, Florence, Roussel, Etienne, Roussel, Jean-Christian, Roussel, Christophe, Roussellier, Patricia, Roy, Christophe, Royer, Daniel, Roze, Jean-Christophe, Rozec, Bertrand, Ruimy, Raymond, Ruppé, Etienne, Ruyer, Olivier, Sabbat, Sébastien, Saghi, Tahar, Saigne, Christophe, Sakek, Necera, Salama, Gilles, Salanoubat, Celia, Salaun-Beretta, Guenaelle, Saliba, Elie, Salles, Gilles, Salmon, Odile, Louis Salomon, Jean, Salord, Jean-Michel, Salvucci, Marina, Samson, Thierry, Sanchez, Richard, Sansot, Dominique, Saplacan, Mihaela, Saroufim, Carlo, Sauder, Philippe, Sautereau, Denis, Savare, Ferdinand, Savatier, Rim, Scemla, Anne, Schendel, Adeline, Schmitt, Anna, Schmitt, François, Schmitt, Alain, Schneerson, Morgane, Schneider, Francis, Schved, Jean-François, Schwebel, Carole, Sebban, Anthony, Secher, Aline, Sédillot, Nicholas, Sedjelmaci, Yacine, Segonds, Christine, Seignovert, Camille, Seknazi, Corinne, Semenescu, Marius, Sément, Arnaud, Semet, Jean-Claude, Semet, Guy, Sennevile, Eric, Serier, Miloud, Serre, Arnaud, Seta, Nathalie, Seyrig, Jacques-Arnaud, Sgro, Eric, Sibony-Prat, Joyce, Sicsic, Jean-Luc, Sifaoui, Farid, Signouret, Thomas, Sigur, Nicolas, Silhadi, Souad, Siméoni, Umberto, Simian, Bernard, Similowski, Thomas, Simon, Georges, Simon, François, Simonin, Catherine, Sirbu, Cristina, Sire, Jean-Marie, Sivadon-Tardy, Valérie, Sivery, Bruno, Slama, Michel, Smati, Salim, Sobesky, Rodolphe, Sokeng-Affoule, Hélène, Sollet, Jean-Pierre, Sommabère, André, Sondag, Daniel, Soraudeau, Florence, Sotto, Albert, Soulie, Bruno, Souply, Laurent, Souquet, Jean-Christophe, Soury, Pierre, Souweine, Bertrand, Stahl, Jean-Paul, Steibach, Marie-Isabelle, Stephan, Robin, Stoclin, Annabelle, Stolidi, Philippe, Strock, Paul, Suatean, Diana, Subra, Jean-François, Sucin, Yves, Suel, Philippe, Sullice, Marc, Szwebel, Tali-Anne, Tacchini, Laurent, Talabani-Boizot, Hana, Talarmin, Jean-Philippe, Taleb, Fethi, Tamalet, Catherine, Tamion, Fabienne, Tandonnet, Olivier, Tankovic, Jacques, Tardy, Véronique, Tassot, Christelle, Taurin, Gregory, Taylor, Sabine, Tchenio, Xavier, Tebib, Jacques, Teillet, Laurent, Teixeira, Antonio, Terki, Mustapha, Tesseydre, Sonia, Texier, Jean-Claude, Texier, Anthony, Thellier, Jean-Paul, Thibaud, Didier, Thibault, Michel, Thibaut, Freddy, Thierry, Jacques, Thoinet, Sylvie, Thomas, Pierre, Thomas, René, Thomas, Yves, Thomas, Caroline, Thore, Jean, Thouret, Jean-Marc, Thouvenin, Maxime, Thuet, Francis, Tigaizin, Ahmed, Tigaud, Sylvestre, Tiry, Catherine, Tissieres, Pierre, Tissot, Alain, Tixier, Anne, Touati, Kamel, Toubia, Marie-Lina, Toullalan, Olivier, Tourani, Jean-Marc, Tourrand, Bernadette, Touze, Yvan, Trabelsi-Jnifen, Asma, Traissac, Laurent, Anh Tran, Tu, Tran, Vanessa, Tricoire, Joelle, Tronchon, Laurent, Trouiller, Sébastien, Trystram, David, Ahmed, Becaid, Tsouria, Tuca, Mirela, Turpin, Mathilde, Vache, Bernard, Vachée, Anne, Vaillant, Christine, Valadier, Patrick, Valayer, Patrick, Valette, Xavier, Vallet, Françis, Van de Velde, Florence, Vanden Einjden, Serge, Vandenesch, François, Vande-perre, Philippe, Varin, Marie-Christine, Vary, Gwenaelle, Vaschalde, Yvan, Vassallo, Matteo, Vasse, Marc, Vasseur, Manica, Vatan, Rémi, Vaucel, Jacques, Vergnaud, Michel, Verhaeghe, Annick, Vermesch-Langlin, Annie, Vernet, Guy, Vernet Garnier, Véronique, Verrier, Virginie, Vessieres, Annie, Vialette, Véronique, Viard, Jean-Paul, Vieillard Baron, Antoine, Vighetto, Alain, Villemain, Marc, Villers, Daniel, Vilque, Jean-Pierre, Vinay, Agnès, Vincent, Didier, Vincent, Pascal, Vincent, Colette, Vincent, Simon, Vinci, Clara, Viole, Didier, Violette, Jérémie, Viquesnel, Gerard, Virlouvet, Anne-Laure, Visentin, Séverine, Vittecoq, Daniel, Vodovar, Dominique, Vrigneaud, Laurence, Vu-Thien, Hoang, Vuotto, Fanny, Wafo, Estelle, Wagner, Michel, Walid, Nicola, Walter, Elisabeth, Watson, Sarah, Weinbreck, Pierre, Weinbronn, Eva, Weiss, Emmanuel, Weitten, Thierry, Welker, Yves, Westeel, Pierre-François, Wink, Olivier, Wintenberger, Claire, Woerther, Paul-Louis, Worcel, Isabelle, Wuillai, Anne, Wurmser, Marc, Xavier, Jacob, Yazdanpanah, Yazdan, Yehia, Aihem, Yvenou, Sterenn, Zagdoun, Elie, Zagozda, Dominique, Zame, Thierry-Pascal, Zamfiri, Oana, Zanaldi, Hélène, Zandecki, Marc, Zaoui, Eric, Zarrouk, Virginie, Zarski, Jean-Pierre, Zavadil, Patrick, Zeller, Valérie, Zerbib, Franck, Zerr, Vincent, Zgarni, Lémia, Zoulim, Fabien, Zoveda, Patrick, Zuber, Pierre, Zumbo, Christian, Charlier, Caroline, Perrodeau, Élodie, Leclercq, Alexandre, Cazenave, Benoît, Pilmis, Benoît, Henry, Benoît, Lopes, Amanda, Maury, Mylène M, Moura, Alexandra, Goffinet, François, Dieye, Hélène Bracq, Thouvenot, Pierre, Ungeheuer, Marie-Noëlle, Tourdjman, Mathieu, Goulet, Véronique, de Valk, Henriette, Lortholary, Olivier, Ravaud, Philippe, and Lecuit, Marc

Published
2017
Full Text
View/download PDF

19. Supplementary Data from Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study

Author

Davids, Matthew S., primary, Roberts, Andrew W., primary, Kenkre, Vaishalee P., primary, Wierda, William G., primary, Kumar, Abhijeet, primary, Kipps, Thomas J., primary, Boyer, Michelle, primary, Salem, Ahmed Hamed, primary, Pesko, John C., primary, Arzt, Jennifer A., primary, Mantas, Margaret, primary, Kim, Su Y., primary, and Seymour, John F., primary

Published
2023
Full Text
View/download PDF

20. Digital Module 18: Automated Scoring

Author

Lottridge, Sue, Burkhardt, Amy, and Boyer, Michelle

Abstract

In this digital ITEMS module, Dr. Sue Lottridge, Amy Burkhardt, and Dr. Michelle Boyer provide an overview of automated scoring. Automated scoring is the use of computer algorithms to score unconstrained open-ended test items by mimicking human scoring. The use of automated scoring is increasing in educational assessment programs because it allows scores to be returned faster at lower cost. In the module, they discuss automated scoring from a number of perspectives. First, they discuss benefits and weaknesses of automated scoring, and what psychometricians should know about automated scoring. Next, they describe the overall process of automated scoring, moving from data collection to engine training to operational scoring. Then, they describe how automated scoring systems work, including the basic functions around score prediction as well as other flagging methods. Finally, they conclude with a discussion of the specific validity demands around automated scoring and how they align with the larger validity demands around test scores. Two data activities are provided. The first is an interactive activity that allows the user to train and evaluate a simple automated scoring engine. The second is a worked example that examines the impact of rater error on test scores. The digital module contains a link to an interactive web application as well as its R-Shiny code, diagnostic quiz questions, activities, curated resources, and a glossary.

Published
2020
Full Text
View/download PDF

21. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Author

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara, Hillmen, Peter, DʼRozario, James, Assouline, Sarit, Owen, Carolyn, Gerecitano, John, Robak, Tadeusz, De la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Humerickhouse, Rod, Punnoose, Elizabeth A., Li, Yan, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad, and Kater, Arnon P.

Published
2018
Full Text
View/download PDF

22. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Author

Thompson, Meghan C., primary, Harrup, Rosemary A., additional, Coombs, Catherine C., additional, Roeker, Lindsey E., additional, Pu, Jeffrey J., additional, Choi, Michael Y., additional, Barr, Paul M., additional, Allan, John N., additional, Šimkovič, Martin, additional, Leslie, Lori, additional, Rhodes, Joanna, additional, Chong, Elise A., additional, Kamdar, Manali, additional, Skarbnik, Alan, additional, Lansigan, Frederick, additional, McCall, Brittany, additional, Saja, Khalid, additional, Dyer, Martin J. S., additional, Walter, Harriet S., additional, Lefebure, Marcus, additional, Thadani-Mulero, Maria, additional, Boyer, Michelle, additional, Biondo, Juliana, additional, Sail, Kavita, additional, Manzoor, Beenish S., additional, Furman, Richard, additional, Bantilan, Kurt S., additional, Goy, Andre, additional, Feldman, Tatyana, additional, Labella, Dominic, additional, Schuster, Stephen J., additional, Park, Jae, additional, Palomba, Lia, additional, Zelenetz, Andrew, additional, Eyre, Toby A., additional, Kater, Arnon P., additional, Seymour, John F., additional, and Mato, Anthony R., additional

Published
2022
Full Text
View/download PDF

23. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe):primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

Author

Kersting, Sabina, Dubois, Julie, Nasserinejad, Kazem, Dobber, Johan A., Mellink, Clemens, van der Kevie-Kersemaekers, Anne Marie F., Evers, Ludo M., de Boer, Fransien, Koene, Harry R., Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A., van der Spek, Ellen, van der Straaten, Hanneke M., Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F.M., Visser, Hein P.J., Houtenbos, Ilse, Idink, Cecile A.M., Issa, Djamila E., Dompeling, Ellen C., van Zaanen, Henk C.T., Veelken, Hendrik, Levenga, Henriette, Tick, Lidwine W., Terpstra, Wim E., Tonino, Sanne H., Boyer, Michelle, Mobasher, Mehrdad, Levin, Mark David, Kater, Arnon P., Kersting, Sabina, Dubois, Julie, Nasserinejad, Kazem, Dobber, Johan A., Mellink, Clemens, van der Kevie-Kersemaekers, Anne Marie F., Evers, Ludo M., de Boer, Fransien, Koene, Harry R., Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A., van der Spek, Ellen, van der Straaten, Hanneke M., Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F.M., Visser, Hein P.J., Houtenbos, Ilse, Idink, Cecile A.M., Issa, Djamila E., Dompeling, Ellen C., van Zaanen, Henk C.T., Veelken, Hendrik, Levenga, Henriette, Tick, Lidwine W., Terpstra, Wim E., Tonino, Sanne H., Boyer, Michelle, Mobasher, Mehrdad, Levin, Mark David, and Kater, Arnon P.

Abstract

Background: Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to determine the activity and safety of 12 cycles of venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated patients with chronic lymphocytic leukaemia who were unfit for fludarabine-based treatment, and whether this could be guided by minimal residual disease status. Methods: We conducted an open-label, randomised, parallel-group, phase 2 trial (HOVON 139/GiVe) at 25 hospitals in the Netherlands. Eligible patients were aged 18 years or older with previously untreated chronic lymphocytic leukaemia, had an ECOG performance status of 0–2, and were unfit for fludarabine-based treatment. All patients received two debulking cycles of intravenous obinutuzumab (100 mg on day 1, 900 mg on day 2, and 1000 mg on days 8, 15, and day 1 of cycle two), followed by fixed-duration venetoclax plus obinutuzumab for 12 cycles (six cycles of intravenous obinutuzumab 1000 mg on day 1 and 12 during 28-day cycles of oral venetoclax, starting with a 5-week ramp-up and then 400 mg once daily until completion of cycle 12). Patients were then randomly assigned (1:1) by minimal residual disease status in peripheral blood, to receive either 12 cycles of venetoclax consolidation irrespective of minimal residual disease or venetoclax consolidation only if minimal residual disease was detected at randomisation. The primary endpoint was undetectable minimal residual disease in bone marrow and no progressive disease 3 months after end of consolidation treatment (or corresponding timepoint) by intention-to-treat. Safety was assessed in all patients who received at least one dose of any study drug. This is the primary endpoint analysis of this trial, which is ongoing and is registered with EudraCT (2015-004985-27). Findings: Between Oct 28, 2016, and May 31, 2018, 70 patients were enrolled

Published
2022

25. Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

Author

Seymour, John F., primary, Wu, Jenny Qun, additional, Popovic, Relja, additional, Eichhorst, Barbara, additional, Hillmen, Peter, additional, Kipps, Thomas J., additional, Langerak, Anton W., additional, Owen, Carolyn, additional, Dubois, Julie, additional, Mellink, Clemens, additional, Van Der Kevie-Kersemaekers, Anne-Marie, additional, Dunbar, Fengjiao, additional, Jiang, Yanwen, additional, Chyla, Brenda, additional, Boyer, Michelle, additional, Thadani-Mulero, Maria, additional, Lefebure, Marcus, additional, Harrup, Rosemary, additional, and Kater, Arnon P., additional

Published
2021
Full Text
View/download PDF

26. Chronic Lymphocytic Leukemia (CLL) Clonal Growth Rate Is Slower Following Venetoclax-Rituximab (VenR): Results from a Minimal Residual Disease (MRD) Model from the Randomized Phase 3 Murano Trial

Author

Kater, Arnon P., primary, Lu, Tong, additional, Langerak, Anton W., additional, Mellink, Clemens, additional, Chyla, Brenda, additional, Wu, Jenny Qun, additional, Boyer, Michelle, additional, Lefebure, Marcus, additional, Jiang, Yanwen, additional, and Seymour, John F., additional

Published
2021
Full Text
View/download PDF

28. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.

Author

Davids, Matthew S, Davids, Matthew S, Roberts, Andrew W, Kenkre, Vaishalee P, Wierda, William G, Kumar, Abhijeet, Kipps, Thomas J, Boyer, Michelle, Salem, Ahmed Hamed, Pesko, John C, Arzt, Jennifer A, Mantas, Margaret, Kim, Su Y, Seymour, John F, Davids, Matthew S, Davids, Matthew S, Roberts, Andrew W, Kenkre, Vaishalee P, Wierda, William G, Kumar, Abhijeet, Kipps, Thomas J, Boyer, Michelle, Salem, Ahmed Hamed, Pesko, John C, Arzt, Jennifer A, Mantas, Margaret, Kim, Su Y, and Seymour, John F

Abstract

PurposeWe previously reported a 44% overall response rate (ORR) with the oral BCL-2 inhibitor venetoclax in a phase I study of relapsed/refractory non-Hodgkin lymphoma (NHL). Complete response (CR) was observed in patients with mantle cell lymphoma [(MCL), 21%, n = 6/28] and follicular lymphoma [(FL), 17%, n = 5/29], and partial response (PR) noted in several patients with Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL). Here, we report the long-term outcomes of these four cohorts.Patients and methodsAll patients (n = 106) received venetoclax monotherapy in dose cohorts of 200 to 1,200 mg daily until disease progression or unacceptable toxicity. ORR, progression-free survival (PFS), duration of response (DoR), and adverse events (AEs) were evaluated.ResultsAt a median follow-up of 38.5 months (range, 30.0-46.5), the median PFS for all 106 patients was 5.4 [95% confidence interval (CI), 3.5-8.4] months (FL, 10.8; MCL, 11.3; MZL, 21.2; and WM, 30.4). The median DoR was 14.9 (95% CI, 9.7-27.6) months (FL, 26.6; MCL, 15.7; MZL, 20.1; and WM, 25.3). Achievement of CR versus PR predicted longer DoR in both MCL (31.5 vs. 10.1 months) and FL (37.6 vs. 9.7 months). All grade hematologic AEs were infrequent: neutropenia (19%), anemia (19%), and thrombocytopenia (17%), with no new cytopenias after 2 years on therapy. Nonhematologic AEs included nausea (49%), diarrhea (46%), fatigue (44%), with decreased incidence after 1 year.ConclusionsVenetoclax monotherapy has a manageable safety profile and achieves durable responses in a subset of patients with FL, MCL, WM, and MZL, particularly in those who achieve CR. Further research is warranted on combination strategies to enhance the durability of response to venetoclax.

Published
2021

29. Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab

Author

Harrup, Rosemary Anne, Kater, Arnon P., Eichhorst, Barbara F., Owen, Carolyn, Chyla, Brenda, Jin, Hyun Yong, Jiang, Yanwen, Chang, Yi Meng, Millen, Rosemary, Lefebure, Marcus, Thadani-Mulero, Maria, Boyer, Michelle, and Seymour, John F.

Published
2023
Full Text
View/download PDF

30. Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Author

Zelenetz, Andrew D., Diefenbach, Catherine S., Herbaux, Charles, Tani, Monica, Houot, Roch, Bastos-Oreiro, Mariana, Tilly, Herve, Gastinne, Thomas, Thieblemont, Catherine, Troy-Barnes, Ethan, Olivieri, Stefano, Kesavan, Murali, Kanwar, Manisha, Barlera, Simona, Hatzi, Katerina, Jiang, Yanwen, Boyer, Michelle, and Morschhauser, Franck

Published
2023
Full Text
View/download PDF

31. Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

Author

Handunnetti, Sasanka, primary, Anderson, Mary Ann, additional, Roberts, Andrew W., additional, Davids, Matthew S., additional, Ma, Shuo, additional, Boyer, Michelle, additional, Arzt, Jennifer, additional, Masud, Abdullah Al, additional, Popovic, Relja, additional, Jacobson, Amanda, additional, Kim, Su Y., additional, and Seymour, John F., additional

Published
2021
Full Text
View/download PDF

32. Time-limited venetoclax-rituximab (VenR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): first presentation of 4-year data from the MURANO study

Author

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Lamanna, Nicole, Kim, Su Young, Wu, Jenny, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, Kater, Arnon, Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Lamanna, Nicole, Kim, Su Young, Wu, Jenny, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, and Kater, Arnon

Published
2020

33. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Author

Kater, Arnon P., Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R., Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, Seymour, John F., Kater, Arnon P., Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R., Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, and Seymour, John F.

Abstract

PURPOSEIn previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine plus rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At the 4-year follow-up, we report long-term outcomes, response to subsequent therapies, and the predictive value of molecular and genetic characteristics.PATIENTS AND METHODSPatients with CLL were randomly assigned to 2 years of venetoclax (VenR for the first six cycles) or six cycles of BR. PFS, overall survival (OS), peripheral-blood minimal residual disease (MRD) status, genomic complexity (GC), and gene mutations were assessed.RESULTSOf 389 patients, 194 were assigned to VenR and 195 to BR. Four-year PFS and OS rates were higher with VenR than BR, at 57.3% and 4.6% (hazard ratio [HR], 0.19; 95% CI, 0.14 to 0.25), and 85.3% and 66.8% (HR, 0.41; 95% CI, 0.26 to 0.65), respectively. Undetectable MRD (uMRD) at end of combination therapy (EOCT) was associated with superior PFS compared with low MRD positivity (HR, 0.50) and high MRD positivity (HR, 0.15). Patients in the VenR arm who received ibrutinib as their first therapy after progression (n = 12) had a reported response rate of 100% (10 of 10 evaluable patients); patients subsequently treated with a venetoclax-based regimen (n = 14) had a reported response rate of 55% (six of 11 evaluable patients). With VenR, the uMRD rate at end of treatment (EOT) was lower in patients with GC than in those without GC (P = .042); higher GC was associated with shorter PFS. Higher MRD positivity rates were seen with BIRC3 and BRAF mutations at EOCT and with TP53, NOTCH1, XPO1, and BRAF mutations at EOT.CONCLUSIONEfficacy benefits with fixed-duration VenR are sustained and particularly durable in patients who achieve uMRD. Salvage therapy with ibrutinib after VenR achieved high response rates. Genetic mutations and GC affected MRD rates and PFS.

Published
2020

34. The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study

Author

Mato, Anthony R., primary, Sharman, Jeff P., additional, Biondo, Juliana M.L., additional, Wu, Mei, additional, Mun, Yong, additional, Kim, Su Y., additional, Humphrey, Kathryn, additional, Boyer, Michelle, additional, Zhu, Qian, additional, and Seymour, John F., additional

Published
2020
Full Text
View/download PDF

35. Caffeine as a perfomance-enhancing drug in rats: sex, dose, housing, and task considerations

Author

Boyer, Michelle, Rees, Stephanie, Quinn, Joanne, Grattan-Miscio, Karen, McCallum, Meghan, and Saari, Matti J.

Subjects
Rats as laboratory animals -- Research, Caffeine -- Influence, Caffeine -- Research, Health, Psychology and mental health
Abstract

Past animal studies of the performance-enhancing properties of stimulant drugs, such as caffeine, may have suffered from a number of procedural and ethical problems. For example, the housing condition of the animals was often not taken into consideration. As well, endurance tests, such as the forced swim task, sometimes involved ethically (and procedurally) questionable interference with natural swimming behaviour. Some of the manipulations, such as attaching a weight to the swimming animal's tail to increase the difficulty of the task and using mortality as a dependent variable, seem grotesque, even unnecessary. In this experiment, the performance-enhancing effects of caffeine in a modified forced swim task and a dominance task were evaluated using male and female rats as subjects (N=60), housed in either enriched or isolated environments. Analysis indicated that rats respond to caffeine as an interactive function of sex, housing, dose, and task characteristics. It was concluded that performance-enhancing properties of stimulant drugs may be the result of a complex interplay of variables, making simple generalizations questionable.

Published
2003

36. Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings

Author

Seymour, John F., primary, Gribben, John G., additional, Davids, Matthew S., additional, Mato, Anthony, additional, Sharman, Jeff P, additional, Cyr, Aimee, additional, Bartkus, Cynthia, additional, Pena, German, additional, Boyer, Michelle, additional, Sharmokh, Simon, additional, Rosenberg, Tanya S, additional, and Wierda, William G., additional

Published
2020
Full Text
View/download PDF

37. Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Author

Kater, Arnon P., primary, Kipps, Thomas J., additional, Eichhorst, Barbara, additional, Hillmen, Peter, additional, D'Rozario, James, additional, Owen, Carolyn, additional, Assouline, Sarit E, additional, Lamanna, Nicole, additional, Robak, Tadeusz J., additional, de la Serna, Javier, additional, Jaeger, Ulrich, additional, Cartron, Guillaume, additional, Montillo, Marco, additional, Mellink, Clemens, additional, Chyla, Brenda J., additional, Wilson, Cameron, additional, Wu, Jenny, additional, Jiang, Yanwen, additional, Lefebure, Marcus, additional, Boyer, Michelle, additional, and Seymour, John F., additional

Published
2020
Full Text
View/download PDF

39. Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results.

Author

Mato, Anthony R., primary, Sharman, Jeff P., additional, Biondo, Juliana, additional, Wu, Mei, additional, Mun, Yong, additional, Kim, Su Young, additional, Humphrey, Kathryn, additional, Boyer, Michelle, additional, Zhu, Qian, additional, and Seymour, John F., additional

Published
2020
Full Text
View/download PDF

40. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

Author

Kater, Arnon P., Seymour, John F., Hillmen, Peter, Eichhorst, Barbara, Langerak, Anton W., Owen, Carolyn, Verdugo, Maria, Wu, Jenny, Punnoose, Elizabeth A., Jiang, Yanwen, Wang, Jue, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad, Kipps, Thomas J., Kater, Arnon P., Seymour, John F., Hillmen, Peter, Eichhorst, Barbara, Langerak, Anton W., Owen, Carolyn, Verdugo, Maria, Wu, Jenny, Punnoose, Elizabeth A., Jiang, Yanwen, Wang, Jue, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad, and Kipps, Thomas J.

Abstract

PURPOSE The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixedduration venetoclax-rituximab compared with bendamustine-rituximab in relapsed/refractory chronic lymphocytic leukemia. With all patients off treatment, we report minimal residual disease (MRD) kinetics and updated outcomes. METHODS Patients were randomly assigned to 2 years of venetoclax plus rituximab during the first six cycles, or six cycles of bendamustine-rituximab. Primary end point was PFS. Safety and peripheral blood (PB) MRD status-at cycle 4, 2 to 3 months after end of combination therapy (EOCT), and every 3 to 6 months thereafter-were secondary end points. RESULTS Of 194 patients, 174 (90%) completed the venetoclax-rituximab phase and 130 (67%) completed 2 years of venetoclax. With a median follow-up of 36 months, PFS and overall survival remain superior to bendamustine-rituximab (hazard ratio, 0.16 [95% CI, 0.12 to 0.23]; and hazard ratio, 0.50 [95% CI, 0.30 to 0.85], respectively). Patients who received venetoclax-rituximab achieved a higher rate of PB undetectable MRD (uMRD; less than 10(-4)) at EOCT (62% v 13%) with superiority sustained through month 24 (end of therapy). Overall, uMRD status at EOCT predicted longer PFS. Among those with detectable MRD, low-level MRD (1024 to less than 10(-2)) predicted improved PFS compared with high-level MRD (1022 or greater). At a median of 9.9 months (range, 1.4 to 22.5 months) after completing fixed-duration venetoclax-rituximab, overall only 12% (16 of 130) of patients developed disease progression (11 high-level MRD, three low-level MRD). At the end of therapy, 70% and 98% of patients with uMRD remained in uMRD and without disease progression, respectively. CONCLUSION With all patients having finished treatment, continued benefit was observed for venetoclaxrituximab compared with bendamustine-rituximab. uMRD rates were durable and predicted longer PFS, which establishes the impact of PB MRD on the benefit of fi

Published
2019

41. Examining the Effects of Changes in Automated Rater Bias and Variability on Test Equating Solutions

Author

Boyer, Michelle

Abstract

Many studies have examined the quality of automated raters, but none have focused on the potential effects of systematic rater error on the psychometric properties of test scores. This simulation study examines the comparability of test scores under multiple rater bias and variability conditions, and addresses questions of their effects on test equating solutions. Effects are characterized by a comparison of equated and observed raw scores and estimates of examinee ability across the bias and variability scenarios. Findings suggest that the presence of, and changes in, rater bias and variability affect the equivalence of total raw scores, particularly at higher and lower ends of the score scale. The effects are shown to be larger where variability levels are higher, and, generally, where more constructed response items are used in the equating. Preliminary findings also suggest that consistently higher rater variability may have a slightly larger negative impact on the comparability of scores than does reducing rater bias and variability under the conditions examined here. Finally, a non-equivalent groups anchor test (NEAT) equating design may be slightly more robust to changes in rater bias and variability than a single group equating design for the bias scenarios investigated.

Published
2018
Full Text
View/download PDF

42. Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Author

Seymour, John F., primary, Kipps, Thomas J., primary, Eichhorst, Barbara F., primary, Hillmen, Peter, primary, D'Rozario, James, primary, Assouline, Sarit, primary, Owen, Carolyn, primary, Robak, Tadeusz, primary, de la Serna, Javier, primary, Jaeger, Ulrich, primary, Cartron, Guillaume, primary, Montillo, Marco, primary, Lamanna, Nicole, primary, Kim, Su Young, primary, Wu, Jenny, primary, Jiang, Yanwen, primary, Wang, Jue, primary, Lefebure, Marcus, primary, Boyer, Michelle, primary, Humphrey, Kathryn, primary, and Kater, Arnon P, primary

Published
2019
Full Text
View/download PDF

43. Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Author

Kater, Arnon P, primary, Wu, Jenny Qun, primary, Dubois, Julie, primary, Bolen, Christopher R, primary, Assaf, Zoe J, primary, Hillmen, Peter, primary, Eichhorst, Barbara F., primary, Eldering, Eric F, primary, Kipps, Thomas J., primary, Langerak, Anton W, primary, Mellink, Clemens, primary, Van Der Kevie-Kersemaekers, Anne-Marie, primary, Owen, Carolyn, primary, Chyla, Brenda J, primary, Punnoose, Elizabeth A, primary, Wang, Jue, primary, Lefebure, Marcus, primary, Boyer, Michelle, primary, Humphrey, Kathryn, primary, Jiang, Yanwen, primary, and Seymour, John F., primary

Published
2019
Full Text
View/download PDF

44. Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study

Author

Deng, Rong, primary, Gibiansky, Leonid, additional, Lu, Tong, additional, Li, Xiaobin, additional, Lu, Dan, additional, Li, Chunze, additional, Girish, Sandhya, additional, Wang, Jue, additional, Boyer, Michelle, additional, Shankar, Noopur, additional, Humphrey, Kathryn, additional, Freise, Kevin J., additional, Salem, Ahmed Hamed, additional, Seymour, John F., additional, Kater, Arnon P., additional, and Miles, Dale, additional

Published
2019
Full Text
View/download PDF

45. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

Author

Kater, Arnon P., primary, Seymour, John F., additional, Hillmen, Peter, additional, Eichhorst, Barbara, additional, Langerak, Anton W., additional, Owen, Carolyn, additional, Verdugo, Maria, additional, Wu, Jenny, additional, Punnoose, Elizabeth A., additional, Jiang, Yanwen, additional, Wang, Jue, additional, Boyer, Michelle, additional, Humphrey, Kathryn, additional, Mobasher, Mehrdad, additional, and Kipps, Thomas J., additional

Published
2019
Full Text
View/download PDF

46. High, durable minimal residual disease negativity (MRD-) with venetoclax plus rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.

Author

Hillmen, Peter, Kater, Arnon P., Seymour, John Francis, Langerak, Anton W., Eichhorst, Barbara, Owen, Carolyn, Assouline, Sarit E., Janssens, Ann, Marlton, Paula, Badoux, Xavier C., Mous, Rogier, Chyla, Brenda, Humerickhouse, Rod, Boyer, Michelle, Humphrey, Kathryn, Jiang, Yanwen, Punnoose, Elizabeth, Wang, Jue, Wu, Qun Jenny, Mobasher, Mehrdad, Hillmen, Peter, Kater, Arnon P., Seymour, John Francis, Langerak, Anton W., Eichhorst, Barbara, Owen, Carolyn, Assouline, Sarit E., Janssens, Ann, Marlton, Paula, Badoux, Xavier C., Mous, Rogier, Chyla, Brenda, Humerickhouse, Rod, Boyer, Michelle, Humphrey, Kathryn, Jiang, Yanwen, Punnoose, Elizabeth, Wang, Jue, Wu, Qun Jenny, and Mobasher, Mehrdad

Published
2018

47. First Prospective Data on Impact of Minimal Residual Disease on Long - Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study

Author

Kater, Arnon P., Hillmen, Peter, Eichhorst, Barbara, Langerak, Anton W., Kipps, Thomas J., Owen, Carolyn, Boyer, Michelle, Humphrey, Kathryn, Punnoose, Elizabeth A., Wang, Jue, Chyla, Brenda, Verdugo, Maria E., Wu, Jenny, Jiang, Yanwen, Mobasher, Mehrdad, Seymour, John F., Kater, Arnon P., Hillmen, Peter, Eichhorst, Barbara, Langerak, Anton W., Kipps, Thomas J., Owen, Carolyn, Boyer, Michelle, Humphrey, Kathryn, Punnoose, Elizabeth A., Wang, Jue, Chyla, Brenda, Verdugo, Maria E., Wu, Jenny, Jiang, Yanwen, Mobasher, Mehrdad, and Seymour, John F.

Published
2018

48. MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Author

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Lamanna, Nicole, Verdugo, Maria E., Punnoose, Elizabeth A., Jiang, Yanwen, Wang, Jue, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad, Kater, Arnon P., Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Lamanna, Nicole, Verdugo, Maria E., Punnoose, Elizabeth A., Jiang, Yanwen, Wang, Jue, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad, and Kater, Arnon P.

Published
2018

49. Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.

Author

Deng, Rong, Gibiansky, Leonid, Lu, Tong, Li, Xiaobin, Lu, Dan, Li, Chunze, Girish, Sandhya, Wang, Jue, Boyer, Michelle, Shankar, Noopur, Humphrey, Kathryn, Freise, Kevin J., Salem, Ahmed Hamed, Seymour, John F., Kater, Arnon P., and Miles, Dale

Subjects
CHRONIC lymphocytic leukemia, LYMPHOCYTIC leukemia, DOSE-response relationship in biochemistry, LOGISTIC regression analysis, RITUXIMAB
Abstract

Exposure–response relationships from a phase 1b (M13-365) and phase 3 (MURANO) study were investigated to assess benefit/risk of venetoclax 400 mg daily plus rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dose intensities were summarized by tertiles of predicted venetoclax steady-state average concentrations based on nominal venetoclax dose (CmeanSS,nominal) for tolerability; exposure–safety analyses used logistic regression. Exposure–progression-free survival (PFS) relationships were assessed using MURANO data, with CmeanSS,nominal as a grouping factor. Covariates were demographics, geographic region, study, baseline disease characteristics, ECOG performance status, responsiveness to prior therapy, and chromosomal abnormalities. There was no significant effect of covariates on grade ≥3 neutropenia/infection or PFS, and no relationship between venetoclax exposure and these endpoints, or venetoclax or rituximab dose intensity. These results support the recommended venetoclax 400 mg daily dose in combination with rituximab in patients with R/R CLL or small lymphocytic leukemia. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

50. MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Author

Seymour, John F., primary, Kipps, Thomas J., additional, Eichhorst, Barbara, additional, Hillmen, Peter, additional, D'Rozario, James, additional, Assouline, Sarit, additional, Owen, Carolyn, additional, Robak, Tadeusz, additional, de la Serna, Javier, additional, Jaeger, Ulrich, additional, Cartron, Guillaume, additional, Montillo, Marco, additional, Lamanna, Nicole, additional, Verdugo, Maria E., additional, Punnoose, Elizabeth A, additional, Jiang, Yanwen, additional, Wang, Jue, additional, Boyer, Michelle, additional, Humphrey, Kathryn, additional, Mobasher, Mehrdad, additional, and Kater, Arnon P., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results